Potential changes to Medicare and private insurance coverage policies regarding weight-loss medications
Web References : References : Cuomo, R
Therefore, clinicians should not assume all barriers will disappear immediately
Gianello (PubMed) Research Focus : Mechanistic Preclinical Research Title : Development of a Human Growth Hormone Peptide Analogue AOD9604 into an Anti-Obesity Drug (Book chapter, Peptides: The Wave of the Future, APSY vol 7, 2001) Authors : Woei-Jia Jiang, Robert Gianello, Mark Heffernan, Esra Ogru, Roksan Libinaki, Frank Ng (SpringerLink) Research Focus : Preclinical Lipid Metabolism Studies (Mice) Title : The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and -AR knockout mice (Endocrinology, Dec 2001) Authors : M
In the UK, semaglutide (Wegovy) and liraglutide (Saxenda) are licensed specifically for weight management, while semaglutide (Ozempic) is licensed only for type 2 diabetes